GlaxoSmithKline Exercises Option to L...

GlaxoSmithKline Exercises Option to License ChemoCentryx, Inc.'s CCR1 ...

There are 1 comment on the BioSpace story from Jan 5, 2012, titled GlaxoSmithKline Exercises Option to License ChemoCentryx, Inc.'s CCR1 .... In it, BioSpace reports that:

GlaxoSmithKline Exercises Option to License ChemoCentryx, Inc. 's CCR1 Inhibitor, CCX354, for the Treatment of Rheumatoid Arthritis /PRNewswire/ -- ChemoCentryx, Inc., today announced that GlaxoSmithKline has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine ... (more)

Join the discussion below, or Read more at BioSpace.

Joan

Toronto, Canada

#1 May 6, 2012

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ChemoCentryx Discussions

Title Updated Last By Comments
News IPO Preview: ChemoCentryx (May '12) May '12 Robson 1
News GSK licenses experimental arthritis treatment f... (May '12) May '12 Robson 1
News GSK Licenses RA Drug from ChemoCentryx (May '12) May '12 Robson 1
News GSK Exercises Option to License ChemoCentryx's ... (May '12) May '12 Robson 1
News GSK obtains exclusive license to ChemoCentryx's... (May '12) May '12 Joan 1
News Drug developer ChemoCentryx has priced its IPO ... (May '12) May '12 Joan 1
News Market Report, "Diabetic Nephropathy - Pipeline... (May '12) May '12 Joan 1
More from around the web